ライフサイエンスコーパス: RIT

1 RIT also promoted the apoptosis-like death of fungal cel

2 RIT appears promising for future cancer therapy.

3 RIT can conceivably target such disease and improve canc

4 RIT clearance was not affected by treatment with HB22.7.

5 RIT of CN with (213)Bi- and (188)Re-labeled specific mAb

6 RIT of fungal cells using specific antibodies labeled wi

7 RIT was associated with changes in concentration of the

8 RIT with radiolabeled antibodies to the CD20 surface ant

9 RIT-mediated haploidentical BMT without TBI may increase

10 RIT-seq profiling identifies both known drug importers a

11 RITs have shown efficacy in refractory hairy cell leukem

12 (n = 24), Cilengitide-treated mice (n = 18), RIT (200-260 mu Ci (90)Y-labeled 1,4,7,10-tetraazacyclod

13 In syngeneic HSCT studies, (211)At-B10-30F11 RIT improved the median survival of leukemic mice in a d

14 tions represents an important advance in 90Y RIT because it facilitates the dependable and cost-effec

15 of a conventional cylindrical ion trap and a RIT of 4 times greater volume show an improvement of 40

16 Furthermore, CD38 has not been explored as a RIT target despite its uniform high expression on malign

17 d BALB/c mice with multiple doses of SS1P, a RIT whose Ab portion targets mesothelin.

18 After RIT, complete response was observed in 6 patients, parti

19 Soon after tracer dose and after RIT, mean SUV-lean of the other 6 responders decreased t

20 6-7 d after the tracer dose, and 5-7 d after RIT to estimate the early response to tracer dose and RI

21 At 33-70 d after RIT, mean SUV-lean of 6 responders markedly declined to

22 was performed at baseline and 33-70 d after RIT.

23 ecline from the baseline value at 37 d after RIT.

24 of tumor and endothelial cells 5 days after RIT compared with tumors from mice given RIT alone.

25 DG uptake in NHL may decline gradually after RIT in responding patients.

26 ped human antimurine antibodies (HAMA) after RIT.

27 tered simultaneously with and 24 hours after RIT, and in the RIT treatment groups, this translated in

28 ith HB22.7 simultaneously and 24 hours after RIT, respectively.

29 fore, simultaneously with, or 24 hours after RIT.

30 FDG PET metabolic data obtained 1-2 mo after RIT correlate well with the ultimate best response of NH

31 ions that range from 27+ to 87+ months after RIT.

32 in vivo therapeutic efficacy was noted after RIT-INP-G3139 administration in a disseminated xenograft

33 variable analyses of the LLQ scores and age, RIT, AMD severity, subfoveal choroidal thickness [SFCT],

34 lizing Abs to Pseudomonas exotoxin, allowing RIT treatment.

35 In all multivariable analyses, RIT had a stronger association than choroidal thickness.

36 conclusion, CMRIT, combining Cilengitide and RIT, significantly increased the efficacy of therapy and

37 timate the early response to tracer dose and RIT.

38 coring the success of both immunotherapy and RIT in the treatment of NHL.

39 n the antifungal activity of macrophages and RIT, suggesting the potential for synergistic action in

40 adult, neonate, and maternal yaws by PCR and RIT clearly demonstrated that, unlike syphilis, there wa

41 Both gamma-radiation and RIT caused cell death via an apoptotic-like pathway with

42 h to consider in radioimmunoscintigraphy and RIT.

43 fficiency, which occurred in two patients at RIT doses that delivered > or = 27 Gy to the lungs.

44 red on 46 patients treated with 1311 anti-B1 RIT as inpatients.

45 Myeloablative (131)I-anti-B1 RIT is relatively well tolerated when given with autolog

46 ho had chemotherapy-sensitive disease before RIT had current PFS and OS rates at 4 years of 55% and 5

47 antation (BMT) with 300 muCi (90)Y-anti-CD45 RIT and CY, without TBI or fludarabine, led to mixed chi

48 ing and disease control supporting anti-CD45 RIT for T-NHL patients.

49 These data suggest that (211)At-anti-CD45 RIT in conjunction with HSCT may be a promising therapeu

50 uated the efficacy and toxicity of anti-CD45 RIT using (211)At in a disseminated murine AML model.

51 ble directly radiolabeled bivalent anti-CD45 RIT.

52 We evaluated anti-CD45-RIT in human (h) and murine (m) T-NHL.

53 ignificant improvement in PFS comparing CHOP-RIT with CHOP-R.

54 as 97% on the CHOP-R arm and 93% on the CHOP-RIT arm (P = .08).

55 as 76% on the CHOP-R arm and 80% on the CHOP-RIT arm (P = .11).

56 e cure rate for mice that received 260 mu Ci RIT increasing from 15 to 53% (P = 0.011).

57 This motif, together with classical RITs, account for up to 90% of all the significantly str

58 In this report, both conventional RIT (directly radiolabeled antibody) and streptavidin-bi

59 1 ratio reported previously for conventional RIT.

60 respectively) compared with the conventional RIT controls (2.6:1, 6.4:1, and 2.9:1, respectively).

61 livering RIT may be superior to conventional RIT when targeting CD45 for the treatment of leukemia an

62 that were markedly superior to conventional RIT.

63 ith tolerable toxicity, whereas conventional RIT with (90)Y-1F5 at a dose of 14.8 MBq (400 micro Ci)

64 compared with mice treated with conventional RIT using (90)Y-labeled anti-hCD45 Ab at 200 muCi.

65 fficacy of pretargeted RIT with conventional RIT using an anti-CD20 antibody.

66 c ratio than that achieved with conventional RIT using the same antibody.

67 ed anti-hCD45 RIT and <1:1 with conventional RIT.

68 nontarget tissues compared with conventional RIT.

69 ratios never exceeded 1:1 with conventional RIT.

70 boratory-scale mass spectrometer with a DAPI-RIT (rectilinear ion trap)-DAPI configuration has been d

71 gest that pretargeted methods for delivering RIT may be superior to conventional RIT when targeting C

72 pairs the clinical efficacy of CD20-directed RIT, imply that novel anti-CD20 MoAbs could also face th

73 Lower-dose RIT (200 mu Ci) combined with Cilengitide resulted in le

74 l compartmentalization of G3139-encapsulated RIT-INPs, resulting in reduced NF-kappaB activation, rob

75 e overall analytical capabilities of the ESI-RIT instrument were demonstrated with the analysis of a

76 firmed to have developed tMDS/tAML following RIT.

77 increase in cures (36 compared with 25% for RIT alone; P = 0.514).

78 e preparation of 131I-labeled antibodies for RIT.

79 has been the traditional target antigen for RIT of non-Hodgkin lymphoma (NHL), studies targeting HLA

80 with relapsed DLBCL should be considered for RIT versus autologous transplantation.

81 helator of (212)Bi, (213)Bi, and (177)Lu for RIT was evaluated in vitro and in vivo.

82 Improved yields are needed for RIT with 90Y-DOTA immunoconjugates to be practical.

83 e of this approach in treatment planning for RIT.

84 s with extended follow-up suggest a role for RIT in chemotherapy-sensitive relapsed DLBCL, even in pa

85 CD45 may represent an alternative target for RIT in B-NHL.

86 e-labeled infusion of (131)I-tositumomab for RIT (January 1990 and April 2003) were reviewed.

87 atmospheric pressure ion (API) sources, four RIT mass analyzers, four sets of ion optical elements, a

88 Fractionated RIT using (90)Y-IT is an effective initial treatment for

89 Microvessel density in tumors from RIT and CMRIT mice was not different.

90 ter RIT compared with tumors from mice given RIT alone.

91 netics of alemtuzumab in 2 different groups: RIT (100 mg alemtuzumab in vivo over 5 days) and myeloab

92 hours were 20:1 using pretargeted anti-hCD45 RIT and <1:1 with conventional RIT.

93 HD-RIT may improve outcomes versus C-HDT in patients with r

94 d PFS were 67% and 48%, respectively, for HD-RIT and 53% and 29%, respectively, for C-HDT.

95 with either high-dose radioimmunotherapy (HD-RIT) using 131I-anti-CD20 (n = 27) or conventional high-

96 eatment-related mortality was 3.7% in the HD-RIT group and 11% in the C-HDT group.

97 was estimated to be.076 at 8 years in the HD-RIT group and.086 at 7 years in the C-HDT group.

98 Patients treated with HD-RIT experienced improved overall survival (OS) (unadjust

99 ilar, although more patients treated with HD-RIT had an elevated pretransplantation level of lactate

100 Patients treated with HD-RIT received individualized therapeutic doses of 131I-to

101 Hence, RIT agents licensed for adult tumors are generally not a

102 ibe our efforts to make new less-immunogenic RITs by identifying and removing T- and B-cell epitopes

103 Recombinant immunotoxin (RIT) therapy is limited in patients by neutralizing Ab r

104 Recombinant immunotoxins (RIT) have been highly successful in cancer therapy due,

105 Recombinant immunotoxins (RITs) are chimeric proteins designed to treat cancer.

106 Recombinant immunotoxins (RITs) are chimeric proteins that are being developed for

107 Recombinant immunotoxins (RITs) are hybrid proteins used to treat cancer.

108 Recombinant immunotoxins (RITs) are potent anticancer agents that have produced ma

109 ascular permeability in an effort to improve RIT of solid tumors.

110 Alemtuzumab concentrations in RIT patients were in excess of that required to kill inf

111 a higher percentage of apoptosis observed in RIT-treated cells.

112 etration, which is especially significant in RIT where background uptake is high.

113 ubscale outcomes, adjusted for age, included RIT, with total LLQ score, "driving," "extreme lighting,

114 Increased RIT was associated significantly with increasing AMD sev

115 eutic radioisotopes into tumors for internal RIT, or chemotherapeutic drugs for synergistically combi

116 correlated with prolonged DA testing (longer RIT) and decreased choroidal thickness.

117 ials with radiolabeled anti-B-cell NHL mAbs, RIT promises to become integral to nuclear medicine prac

118 nted with CRT-D or an ICD, enrolled in MADIT-RIT.

119 on Trial-Reduce Inappropriate Therapy (MADIT-RIT) randomized patients with a primary prophylactic ICD

120 on Trial-Reduce Inappropriate therapy (MADIT-RIT) trial showed a significant reduction in inappropria

121 on Trial-Reduce Inappropriate Therapy [MADIT-RIT], Avoid Delivering Therapies for Non-sustained Arrhy

122 e, the deimmunized toxin can be used to make RITs targeting other antigens, and the approach we descr

123 /116 [13%]) had a significantly greater mean RIT compared with eyes without RPD in any AMD severity g

124 In mice, RIT and LOP induced mild ER stress and inhibition of sar

125 peptide ChL6; n = 46), and combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250

126 This multiplexed RIT mass spectrometer employs an array of four millimete

127 we used this information to construct mutant RITs that are highly cytotoxic and do not stimulate T-ce

128 Myeloablative RIT and ASCT is a safe and effective therapeutic option

129 ximab)-conjugated lipopolyplex nanoparticle (RIT-INP)- and Bcl-2-targeted antisense G3139 as archetyp

130 Comparing amounts of RIT delivered in vivo and in vitro can explain tumor res

131 The combination of RIT with topotecan substantially reduced growth of relat

132 In this article, the basic concepts of RIT are reviewed with important milestones in its develo

133 ems make neutralizing Abs after one cycle of RIT, preventing repeated dosing.

134 sults, and avenues for future development of RIT are discussed.

135 ate neutralizing Ab levels, making dosing of RIT possible in mice already immune to RIT.

136 ethod that can increase the effectiveness of RIT, while decreasing the toxicities associated with dir

137 , suggesting that the therapeutic effects of RIT may result from changes in the inflammatory response

138 A) has been shown to augment the efficacy of RIT and decrease toxicity compared with a directly label

139 tumor site and thus improve the efficacy of RIT by combination with other treatment modalities.

140 s suggest that the antimicrobial efficacy of RIT involves killing through promotion of fungal cell ap

141 To compare the efficacy of RIT with that of amphotericin B, we infected AJ/Cr mice

142 toxicity, and become the next generation of RIT.

143 demonstrate that DDR1 is a key modulator of RIT activity and represents a novel therapeutic strategy

144 exploration of the therapeutic potential of RIT has been challenged by the absence of adequate ligan

145 ne physicians with a better understanding of RIT capabilities and limitations in B-cell NHL and their

146 nvolvement, when needed, to allow the use of RIT and can suppress HAMA responses.

147 for the expected widespread clinical use of RIT in the management of B-cell NHL, alone or in combina

148 To enhance the therapeutic efficacy of RITs, we conducted a kinome RNAi sensitization screen, w

149 er analysis of species where a low number of RITs were predicted revealed a highly conserved structur

150 fore, we investigated the effects of DDR1 on RIT.

151 RG7787 is a clinically optimized RIT consisting of a humanized anti-mesothelin Fab fused

152 tly than the early data after tracer dose or RIT.

153 After irradiation or RIT, the cells were plated for colony-forming units (CFU

154 d patient-specific exposure data, outpatient RIT with nonmyeloablative doses of 131I should be feasib

155 Implementing outpatient RIT should make the therapy more widely available and mo

156 shown a clear advantage in sensitivity over RIT.

157 We therefore conducted pretargeted (P)RIT studies to augment the efficacy in mice of therapy u

158 NIE, a probabilistic approach for predicting RITs.

159 Pretargeted RIT (PRIT) using antibody-streptavidin (Ab-SA) construct

160 Pretargeted RIT using a covalent conjugate of the 1F5 anti-CD20 Ab w

161 Pretargeted RIT with 29.6 MBq (800 micro Ci) (90)Y-DOTA-biotin cured

162 and ABC-DLBCL xenografts with a pretargeted RIT (PRIT) system directed against the CD20 antigen.

163 progression-free survival after pretargeted RIT varied depending upon the lymphoma cell line used, w

164 ntibody) and streptavidin-biotin pretargeted RIT (PRIT) directed against the CD38 antigen were assess

165 e results suggest that anti-CD20 pretargeted RIT may be superior to conventional radiolabeled antibod

166 trates the marked superiority of pretargeted RIT for each of the antigenic targets with more complete

167 that clinical implementation of pretargeted RIT methods will provide a meaningful prolongation of su

168 ity, and therapeutic efficacy of pretargeted RIT with conventional RIT using an anti-CD20 antibody.

169 Nine patients received 3-step pretargeted RIT: (a) 160 mg/m2 of CC49 fusion protein, (b) synthetic

170 e is substantially reduced using pretargeted RIT.

171 no prior myeloablative therapy, and no prior RIT.

172 We have produced RITs that contain PE38, a portion of the bacterial prote

173 R-RIT showed a favorable benefit and risk profile in advan

174 openia or leukocytopenia was observed in 5 R-RIT patients, lasting 4-129 d.

175 h Hodgkin lymphoma (HL), were eligible for R-RIT (a priori criteria-based target-to-bone marrow ratio

176 ese results warrant further exploration of R-RIT in larger phase II clinical trials.

177 activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed lymphoma or multiple

178 Both multiple myeloma patients receiving R-RIT experienced stabilization of disease.

179 Radioimmunotherapy (RIT) for pediatric tumors remains in its infancy despite

180 Radioimmunotherapy (RIT) for treatment of hematologic malignancies frequentl

181 Radioimmunotherapy (RIT) is a new treatment modality for B-cell non-Hodgkin'

182 Radioimmunotherapy (RIT) is a promising treatment approach for B-cell lympho

183 Radioimmunotherapy (RIT) options for T-cell non-Hodgkin lymphomas (T-NHLs) a

184 Radioimmunotherapy (RIT) prolongs the survival of mice infected with Cryptoc

185 Radioimmunotherapy (RIT) using (131)I-tositumomab has been used successfully

186 Radioimmunotherapy (RIT) using monoclonal antibodies labeled with beta-emitt

187 Radioimmunotherapy (RIT) with 90Y-labeled immunoconjugates has shown promise

188 Radioimmunotherapy (RIT) with alpha-emitting radionuclides is an attractive

189 Radioimmunotherapy (RIT) with yttrium-90 ((90)Y)-labeled anti-CD20 antibody

190 Radioimmunotherapy (RIT), a therapy targeted to tumor cells, is a modality t

191 (90)Y-DOTA-peptide-Lym-1 radioimmunotherapy (RIT).

192 mor quantification after radioimmunotherapy (RIT) was investigated for SPECT imaging with an ultra-hi

193 mmunodetection (RID) and radioimmunotherapy (RIT).

194 radioimmunodetection and radioimmunotherapy (RIT).

195 ontact with 131I anti-B1 radioimmunotherapy (RIT) patients released immediately after therapeutic inf

196 Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation doses to tumor sites

197 131I-anti-B1 (CD20) radioimmunotherapy (RIT) is a promising approach for treatment of non-Hodgki

198 imen employing anti-CD45 radioimmunotherapy (RIT) replacing total body irradiation (TBI) before haplo

199 Clinical radioimmunotherapy (RIT) of solid tumors holds great promise, but as yet has

200 mpared with conventional radioimmunotherapy (RIT) and at the same time preserve the efficiency of tum

201 control by CD20-directed radioimmunotherapy (RIT), but had no impact on targeting CD45.

202 al yttrium chelators for radioimmunotherapy (RIT) have been prepared via a convenient and high-yield

203 dosimetry and (90)Y for radioimmunotherapy (RIT).

204 roceeded to fractionated radioimmunotherapy (RIT) only if a repeat BM biopsy demonstrated clearing of

205 agnosis and 2 years from radioimmunotherapy (RIT) for previously treated patients, and 4.6 years from

206 odgkin's lymphoma (NHL), radioimmunotherapy (RIT) has finally come of age as a new therapeutic modali

207 The usefulness of radioimmunotherapy (RIT) for infectious diseases was recently demonstrated f

208 ds in the development of radioimmunotherapy (RIT) for non-Hodgkin's lymphoma (NHL) from a single clin

209 The efficacy of radioimmunotherapy (RIT) for patients with relapsed non-Hodgkin lymphoma (NH

210 ut the potential role of radioimmunotherapy (RIT) in the management of plasmacytomas and multiple mye

211 the clinical success of radioimmunotherapy (RIT).

212 nal beam radiotherapy or radioimmunotherapy (RIT), which joins the selectivity of antibody targeting

213 (Abs) and of pretargeted radioimmunotherapy (RIT) using Ab-streptavidin (SA) conjugates, followed by

214 Pretargeted radioimmunotherapy (RIT) using CC49 fusion protein, comprised of CC49-(scFv)

215 Pretargeted radioimmunotherapy (RIT) using streptavidin (sAv)-conjugated antibodies befo

216 cancer is responsive to radioimmunotherapy (RIT), a systemic targeted radiation modality, complete a

217 iodine I-131 tositumomab radioimmunotherapy (RIT).

218 novel strategy is to use radioimmunotherapy (RIT) with fungal-binding monoclonal antibodies (mAbs) la

219 llogeneic HCT data using radioimmunotherapy (RIT) and focuses on recent trials involving patients at

220 momab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory C

221 t antibody (conventional radioimmunotherapy [RIT]).

222 geted radiation therapy (radioimmunotherapy, RIT) employs a bifunctional ligand that can effectively

223 In contrast to conventional RID/RIT where the radionuclides and oncotropic vector molecu

224 HHs) with alcohol and the HIV PIs ritonavir (RIT) and lopinavir (LOP).

225 ivalent to an individual exposed to the same RIT patients was 2.9 +/- 0.4 mSv (290 +/- 40 mrem).

226 me-scale RNA interference target sequencing (RIT-seq) screens in Trypanosoma brucei, revealing the tr

227 survival compared with conventional one-step RIT.

228 d on neovasculature, could increase systemic RIT efficacy of therapy in a human breast cancer tumor m

229 of topotecan and the specificity of systemic RIT to establish a novel therapy for solid tumors in an

230 Bacterial Rho-independent terminators (RITs) are important genomic landmarks involved in gene r

231 examined by PCR and rabbit infectivity test (RIT), were all negative.

232 ined by PCR and the rabbit infectivity test (RIT).

233 antibodies, or the rabbit inoculation test (RIT).

234 local functional measurements of DA testing (RIT) and choroidal thickness are associated with patient

235 m at 40 d is more rapid after FIT (97%) than RIT (36.5%), irrespective of blood myeloid engraftment.

236 We conclude that RIT is more effective than amphotericin B against system

237 These results demonstrate that RIT with an anti-breast mucin MAb does not result in the

238 encountered, there is growing evidence that RIT can have a significant impact on the treatment of ca

239 Dosimetry calculations showed that RIT was approximately 1,000-fold more efficient in killi

240 The RIT mass spectrometer, which was assembled in two differ

241 ompared favorably with the untreated and the RIT alone groups, which had survival rates of 38% and 43

242 removing T- and B-cell epitopes to hide the RIT from the immune system.

243 (ii) The RIT can also be operated as a continuous rf/dc mass filt

244 ocyte counts were significantly lower in the RIT group persisting beyond 6 months after transplantati

245 ify and silence human B-cell epitopes in the RIT HA22.

246 sion of agonist peptides of human C5a in the RIT scheme results in improved tumor responses without a

247 usly with and 24 hours after RIT, and in the RIT treatment groups, this translated into the greatest

248 The mass resolution (50% definition) of the RIT in the trapping mode (radial ion ejection) is approx

249 The demonstrated capabilities of the RIT include tandem mass spectrometry, a mass resolution

250 duced dissociation (CID) capabilities of the RIT instrument were evaluated by measuring isolation eff

251 o Pseudomonas exotoxin, the component of the RIT that elicits the neutralizing Ab response.

252 A which consists of the toxin moiety of the RIT, and used this information to make LMB-T18 in which

253 from the higher ion trapping capacity of the RIT.

254 ce using continuous rf/dc filtering with the RIT.

255 play library containing Fvs that bind to the RITs.

256 first a tracer dose of 131I-anti-B1 and then RIT, each preceded by infusion of unlabeled anti-B1.

257 py (EBRT) and internal radioisotope therapy (RIT) has been widely used for clinical cancer treatment.

258 Optimism remains that these RIT approaches will improve the cure rates of allogeneic

259 The toxin portion of this RIT (LR-LO10) can be used with Fvs targeting other cance

260 me of this study was the rod intercept time (RIT), which is defined as the time for a participant's v

261 rk adaptometer measuring rod intercept time (RIT).

262 linical trials of (90)Y-ibritumomab tiuxetan RIT for relapsed or refractory B-cell non-Hodgkin's lymp

263 Single-dose (90)Y ibritumomab tiuxetan RIT has an acceptable safety profile in relapsed NHL pat

264 eated safely with (90)Y-ibritumomab tiuxetan RIT on the basis of a fixed, weight-adjusted dosing sche

265 let count) toxicity when HB22.7 was added to RIT.

266 was also unchanged when HB22.7 was added to RIT.

267 ng of RIT possible in mice already immune to RIT.

268 It is hypothesized that improvements to RIT of adenocarcinoma can be realized by inclusion of va

269 not increase resistance of C. neoformans to RIT in vivo.

270 ll with the ultimate best response of NHL to RIT, more significantly than the early data after tracer

271 We assessed the tumor metabolic response to RIT using FDG PET.

272 ned B cells from patients with antibodies to RITs, isolated the corresponding variable fragments (Fvs

273 e rapidly than reduced intensity transplant (RIT) at day 0, although the nadir is similar in both at

274 ioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-

275 utcome of reduced-intensity transplantation (RIT) in a cohort of 48 consecutive patients with relapse

276 oning allogeneic stem cell transplantations (RITs) could impair immune reconstitution and reduce dono

277 ctrometer based on the rectilinear ion trap (RIT) analyzer was designed and constructed for simultane

278 er based on a rectilinear geometry ion trap (RIT) has been built, and its performance has been charac

279 tal ion trap (DIT) and rectilinear ion trap (RIT) have been proven to be very useful technology in th

280 e instrument employs a rectilinear ion trap (RIT) mass analyzer and is battery-operated, hand-portabl

281 A rectilinear ion trap (RIT) mass analyzer was incorporated into a mass spectrom

282 g surface, and a novel rectilinear ion trap (RIT) mass analyzer.

283 mass spectrometer with rectilinear ion trap (RIT) mass analyzers was designed, constructed, and chara

284 first mass filter is a rectilinear ion trap (RIT) operated in a continuous mass-selective mode to tra

285 46), and combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 microg/dose; n = 4

286 esults strongly support the concept of using RIT as an antimicrobial modality.

287 rial infections, but the mechanisms by which RIT is effective against microbes are uncertain.

288 they share several tumor antigens for which RIT agents are now available.

289 HL is currently the only indication in which RIT has been proven to be effective, clinical trials are

290 ed cancer have frequently been achieved with RIT as a single agent.

291 combining CHOP-R induction chemotherapy with RIT consolidation and/or extended rituximab maintenance

292 When compared with RIT alone, there was no significant additional hematolog

293 was decreased in CMRIT tumors compared with RIT tumors at 6 days (ANOVA, P < 0.05).

294 ciation was the LLQ subscale of driving with RIT (r =-0.97, P < 0.001).

295 ar results in other cancers seem likely with RIT in combination therapy.

296 in the groups treated with RIT alone or with RIT and HB22.7 (CMIT), the reduction in tumor volume was

297 w blood vessel growth and may synergize with RIT to increase efficacy.

298 Within the groups treated with RIT alone or with RIT and HB22.7 (CMIT), the reduction i

299 In PHHs, treatment with RIT and LOP or alcohol alone increased messenger RNA of

300 PCR results correlated well with RIT results.